 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. NASDAQ:HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced an expansion to the Cooperative Research and Development Agreement CRADA that the company had previously entered into with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear D 